Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Rare Disease Products Mostly Approved With Regulatory Flexibility, NORD "Catalog" Finds

This article was originally published in The Pink Sheet Daily

Executive Summary

NORD makes the case that FDA should codify unconventional approaches by arguing that the agency already uses them for two-thirds of its orphan approvals.

You may also be interested in...

PDUFA VI: NORD Wants Reviewers To Be More Accessible

As rare disease experts become part of orphan drug reviews, stakeholder group says they also should be more accessible to the public.

Rare Disease Integration Into FDA Reviews Will Grow Under PDUFA VI

Stakeholders wonder about impact of placing orphan drug program staff "into review teams" as part of next iteration of user fee program.

Regulatory Flexibility For Rare Diseases: How Do You Routinize Elasticity?

FDA tries to MaPP out how and when reviewers can be flexible, moving from 'one-off' to 'boutique' evaluation.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts